Prostaglandin E2 synthesizing enzymes in rheumatoid arthritis B cells and the effects of B cell depleting therapy on enzyme expression

PLoS ONE

Volumn 6, Issue 1, 2011, Pages

  Gheorghe, Karina Roxana ^a   Thurlings, Rogier M ^b   Westman, Marie ^a   Boumans, Maartje J ^b   Malmström, Vivianne ^a   Trollmo, Christina ^a   Korotkova, Marina ^a,c   Jakobsson, Per Johan ^a   Tak, Paul Peter ^b  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b UNIVERSITY OF AMSTERDAM   (Netherlands)

^c Actar AB   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; INTERLEUKIN 1BETA; INTERLEUKIN 6; METHOTREXATE; MICROSOMAL PROSTAGLANDIN E2 SYNTHASE 1; NONSTEROID ANTIINFLAMMATORY AGENT; PREDNISONE; PROSTAGLANDIN E; PROSTAGLANDIN SYNTHASE; RITUXIMAB; UNCLASSIFIED DRUG; ISOMERASE; PROSTAGLANDIN E SYNTHASE; PROSTAGLANDIN E2;

ARTICLE; B CELL DEPLETION; B LYMPHOCYTE; CELL SELECTION; CLINICAL ARTICLE; COMPUTER ANALYSIS; CONTROLLED STUDY; DRUG RESPONSE; ENZYME ANALYSIS; ENZYME INDUCTION; ENZYME REGULATION; FLOW CYTOMETRY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMAGE ANALYSIS; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; JOINT BIOPSY; LYMPHOCYTE ACTIVATION; MONONUCLEAR CELL; PROTEIN EXPRESSION; RHEUMATOID ARTHRITIS; SIGNAL TRANSDUCTION; SYNOVIAL FLUID; SYNOVIUM; BIOSYNTHESIS; CELL CULTURE; ENZYMOLOGY; IMMUNOLOGY; INFLAMMATION; LYMPHOCYTE DEPLETION; METHODOLOGY; PATHOLOGY;

ARTHRITIS, RHEUMATOID; B-LYMPHOCYTES; CELLS, CULTURED; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; DINOPROSTONE; HUMANS; INFLAMMATION; INTERLEUKIN-1BETA; INTERLEUKIN-6; INTRAMOLECULAR OXIDOREDUCTASES; LYMPHOCYTE DEPLETION; SYNOVIAL MEMBRANE;

EID: 79551570268     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0016378     Document Type: Article

References (34)

1. Steiner G, Smolen J (2002) Autoantibodies in rheumatoid arthritis and their clinical significance. Arthritis Res 4 Suppl 2: S1-S5.
2. Cantaert T, Kolln J, Timmer T, van der Pouw Kraan TC, Vandooren B, et al. (2008) B lymphocyte autoimmunity in rheumatoid synovitis is independent of ectopic lymphoid neogenesis. J Immunol 181: 785-794.
3. Klimiuk PA, Goronzy JJ, Bjor nsson J, Beckenbaugh RD, Weyand CM (1997) Tissue cytokine patterns distinguish variants of rheumatoid synovitis. Am J Pathol 151: 1311-1319.
4. Takemura S, Klimiuk PA, Braun A, Goronzy JJ, Weyand CM (2001) T cell activation in rheumatoid synovium is B cell dependent. J Immunol 167: 4710-4718.
5. Lund FE, Randall TD. Effector and regulatory B cells: modulators of CD4(+) T cell immunity. Nat Rev Immunol 10: 236-247.
6. Dorner T, Kinnman N, Tak PP. Targeting B cells in immune-mediated inflammatory disease: A comprehensive review of mechanisms of action and identification of biomarkers. Pharmacol Ther 125: 464-475.
7. Thurlings RM, Vos K, Wijbrandts CA, Zwinderman AH, Gerlag DM, et al. (2008) Synovial tissue response to rituximab: mechanism of action and identification of biomarkers of response. Ann Rheum Dis 67: 917-925.
8. Sheibanie AF, Khayrullina T, Safadi FF, Ganea D (2007) Prostaglandin E2 exacerbates collagen-induced arthritis in mice through the inflammatory interleukin-23/interleukin-17 axis. Arthritis Rheum 56: 2608-2619.
9. Yao C, Sakata D, Esaki Y, Li Y, Matsuoka T, et al. (2009) Prostaglandin E2-EP4 signaling promotes immune inflammation through Th1 cell differentiation and Th17 cell expansion. Nat Med 15: 633-640.
10. Korotkova M, Westman M, Gheorghe KR, af Klint E, Trollmo C, et al. (2005) Effects of antirheumatic treatments on the prostaglandin E2 biosynthetic pathway. Arthritis Rheum 52: 3439-3447.
11. Siegle I, Klein T, Backman JT, Saal JG, Nusing RM, et al. (1998) Expression of cyclooxygenase 1 and cyclooxygenase 2 in human synovial tissue: differential elevation of cyclooxygenase 2 in inflammatory joint diseases. Arthritis Rheum 41: 122-129.
12. Sano H, Hla T, Maier JA, Crofford LJ, Case JP, et al. (1992) In vivo cyclooxygenase expression in synovial tissues of patients with rheumatoid arthritis and osteoarthritis and rats with adjuvant and streptococcal cell wall arthritis. J Clin Invest 89: 97-108.
13. Stichtenoth DO, Thoren S, Bian H, Peters-Golden M, Jakobsson PJ, et al. (2001) Microsomal prostaglandin E synthase is regulated by proinflammatory cytokines and glucocorticoids in primary rheumatoid synovial cells. J Immunol 167: 469-474.
14. Uematsu S, Matsumoto M, Takeda K, Akira S (2002) Lipopolysaccharidedependent prostaglandin E(2) production is regulated by the glutathionedependent prostaglandin E(2) synthase gene induced by the Toll-like receptor 4/ MyD88/NF-IL6 pathway. J Immunol 168: 5811-5816.
15. Inoue H, Takamori M, Shimoyama Y, Ishibashi H, Yamamoto S, et al. (2002) Regulation by PGE2 of the production of interleukin-6, macrophage colony stimulating factor, and vascular endothelial growth factor in human synovial fibroblasts. Br J Pharmacol 136: 287-295.
16. Kunisch E, Jansen A, Kojima F, Loffler I, Kapoor M, et al. (2009) Prostaglandin E2 differentially modulates proinflammatory/prodestructive effects of TNFalpha on synovial fibroblasts via specific E prostanoid receptors/cAMP. J Immunol 183: 1328-1336.
17. Ryan EP, Pollock SJ, Murant TI, Bernstein SH, Felgar RE, et al. (2005) Activated human B lymphocytes express cyclooxygenase-2 and cyclooxygenase inhibitors attenuate antibody production. J Immunol 174: 2619-2626.
18. Murn J, Alibert O, Wu N, Tendil S, Gidrol X (2008) Prostaglandin E2 regulates B cell proliferation through a candidate tumor suppressor, Ptger4. J Exp Med 205: 3091-3103.
19. Mongini PK, Inman JK, Han H, Fattah RJ, Abramson SB, et al. (2006) APRIL and BAFF promote increased viability of replicating human B2 cells via mechanism involving cyclooxygenase 2. J Immunol 176: 6736-6751.
20. Arras M, Louahed J, Simoen V, Barbarin V, Misson P, et al. (2006) B lymphocytes are critical for lung fibrosis control and prostaglandin E2 regulation in IL-9 transgenic mice. Am J Respir Cell Mol Biol 34: 573-580.
21. Westman M, Korotkova M, af Klint E, Stark A, Audoly LP, et al. (2004) Expression of microsomal prostaglandin E synthase 1 in rheumatoid arthritis synovium. Arthritis Rheum 50: 1774-1780.
22. Prevoo ML, van't Hof MA, Kuper HH, van Leeuwen MA, van de Putte LB, et al. (1995) Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum 38: 44-48.
23. van Gestel AM, Haagsma CJ, van Riel PL (1998) Validation of rheumatoid arthritis improvement criteria that include simplified joint counts. Arthritis Rheum 41: 1845-1850.
24. Kraan MC, Reece RJ, Smeets TJ, Veale DJ, Emery P, et al. (2002) Comparison of synovial tissues from the knee joints and the small joints of rheumatoid arthritis patients: Implications for pathogenesis and evaluation of treatment. Arthritis Rheum 46: 2034-2038.
25. Ulfgren AK, Lindblad S, Klareskog L, Andersson J, Andersson U (1995) Detection of cytokine producing cells in the synovial membrane from patients with rheumatoid arthritis. Ann Rheum Dis 54: 654-661.
26. Haringman JJ, Vinkenoog M, Gerlag DM, Smeets TJ, Zwinderman AH, et al. (2005) Reliability of computerized image analysis for the evaluation of serial synovial biopsies in randomized controlled trials in rheumatoid arthritis. Arthritis Res Ther 7: R862-867.
27. Bernard MP, Phipps RP (2007) CpG oligodeoxynucleotides induce cyclooxygenase- 2 in human B lymphocytes: implications for adjuvant activity and antibody production. Clin Immunol 125: 138-148.
28. Duddy ME, Alter A, Bar-Or A (2004) Distinct profiles of human B cell effector cytokines: a role in immune regulation? J Immunol 172: 3422-3427.
29. Jacobi AM, Dorner T (2010) Current aspects of anti-CD20 therapy in rheumatoid arthritis. Curr Opin Pharmacol 10: 316-321.
30. Teng YK, Levarht EW, Toes RE, Huizinga TW, van Laar JM (2009) Residual inflammation after rituximab treatment is associated with sustained synovial plasma cell infiltration and enhanced B cell repopulation. Ann Rheum Dis 68: 1011-1016.
31. Lee H, Trott JS, Haque S, McCormick S, Chiorazzi N, et al. (2010) A Cyclooxygenase-2/Prostaglandin E2 Pathway Augments Activation-Induced Cytosine Deaminase Expression within Replicating Human B Cells. J Immunol.
32. Alvarez-Soria MA, Largo R, Santillana J, Sanchez-Pernaute O, Calvo E, et al. (2006) Long term NSAID treatment inhibits COX-2 synthesis in the knee synovial membrane of patients with osteoarthritis: differential proinflammatory cytokine profile between celecoxib and aceclofenac. Ann Rheum Dis 65: 998-1005.
33. Hinz B, Brune K, Pahl A (2000) Cyclooxygenase-2 expression in lipopolysaccharide- stimulated human monocytes is modulated by cyclic AMP, prostaglandin E(2), and nonsteroidal anti-inflammatory drugs. Biochem Biophys Res Commun 278: 790-796.
34. Pino MS, Nawrocki ST, Cognetti F, Abruzzese JL, Xiong HQ, et al. (2005) Prostaglandin E2 drives cyclooxygenase-2 expression via cyclic AMP response element activation in human pancreatic cancer cells. Cancer Biol Ther 4: 1263-1269.